Prostate Cancer, Prostate Cancer research hub

LAVA1207-001/LAVA1207-002 A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of LAVA-1207, a PSMA-targeting bispecific γδ-T cell engager, alone or with low dose interleukin-2 or Pembrolizumab, in patients with therapy refractory metastatic castration resistant prostate cancer

This study is testing a new drug, LAVA-1207, for men with prostate cancer that has spread and isn't responding to other treatments. Researchers want to see if it's safe, how well it works, and if combining it with other drugs like Pembrolizumab helps shrink the cancer.